Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
Hematologic Malignancies
DRUG: GSK21110183
Physical exam, Screening, Days -3, 8, At the start of each additional Cycle|Electrocardiogram (ECG), Days -3, -2, -1, 8, 15, At the start of each additional Cycle|Vital signs, Screening, Days -3, -2, -1, 8, 15, At the start of each additional Cycle|Transthoracic Echocardiogram (TTE)/Multiple Gated Acquisition (MUGA) Scans, Screening, Additionally as needed|Clinical Laboratory assessments, Screening, Days -3, 1, 8, 15, At the start of each additional Cycle|ECOG Peformance Status, Screening, Days -3, 8, At the start of each additional Cycle|PK - Maximum observed plasma concentraion (Cmax), Days -3, -2, -1, 8, 15|PK - time to Cmax [tmax] (Maximum observed plasma concentration), Days -3, -2, -1, 8, 15|PK - Area under the plasma concentration-time curve (AUC(0-t)), Days -3, -2, -1, 8, 15|PK - Apparent terminal phase elimination rate constant, Days -3, -2, -1, 8, 15|PK - Apparent terminal phase half-life (t1/2), Days -3, -2, -1, 8, 15|PK - oral clearance (CL/F), Days -3, -2, -1, 8, 15
Metabolite Profiling, Days -3, 8
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.